Alzamend Neuro, Inc.’s (NASDAQ: ALZN) stock has had a tremendous increase, surging 468.26% to $11.55 on the company’s announcement of a major new clinical trial agreement. This sharp rise in the stock price reflects the market’s enthusiasm for Alzamend’s most recent endeavor.
Alzamend Formed Strategic Partnership
Alzamend and Massachusetts General Hospital, a renowned clinical education and research organization connected to Harvard Medical School, have partnered. The primary goal of this partnership is to carry out an innovative Phase II clinical trial of AL001, a potentially effective therapy for post-traumatic stress disorder (PTSD).
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Given Massachusetts General Hospital’s standing as the biggest hospital-based research center and its international renown, the trial’s significance is further highlighted by the choice of the institution as the contract research organization (CRO).
The study’s chief investigator will be Harvard University Associate Professor of Radiology Dr. Ovidiu Andronesi, MD, PhD. Dr. Andronesi’s broad experience in radiology and metabolic imaging will be very helpful when comparing AL001’s effectiveness against that of current lithium salts.
Evaluating AL001: A Novel Approach to PTSD Treatment
This novel trial’s main objective is to examine the rise in lithium levels in the brain and its structures between PTSD patients treated with AL001 and a routinely available lithium salt. During treatment, Alzamend measures the amount of lithium in patients’ brains in an effort to find the lowest effective dose of AL001 that is comparable to the safety and effectiveness of conventional lithium salts.
It is expected that this study will be crucial to fulfilling the regulatory safety standards under the Section 505(b)(2) pathway, which makes it easier for the US Food and medication Administration (FDA) to approve innovative medication formulations or delivery methods.
The FDA-approved lithium salts currently on the market are limited in their therapeutic window and need frequent therapeutic medication monitoring to prevent side effects. AL001 has the potential to overcome these drawbacks. By lowering the hazards connected with traditional lithium therapies and increasing brain bioavailability, Alzamend’s method may provide a safer and more efficient substitute.
